Liver transplantation in metastatic colorectal cancer: are we ready for it?


Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
05 2023
Historique:
received: 01 09 2022
accepted: 17 02 2023
revised: 10 02 2023
medline: 1 5 2023
pubmed: 7 3 2023
entrez: 6 3 2023
Statut: ppublish

Résumé

Colorectal cancer (CRC) is a prevalent disease worldwide, with more than 50% of patients developing metastases to the liver. Five-year overall survival remains modest among patients with metastatic CRC (mCRC) treated with conventional therapies however, liver transplantation in a highly selected population can improve clinical outcomes with an impressive 5-year overall survival of 83%. Despite liver transplantation appearing to be a promising therapeutical option for well-selected patients with mCRC with the liver-limited disease, these data come from small monocentric trials which included a heterogeneous population. Currently, several clinical trials are evaluating liver transplantation in this scenario, aiming for a more accurate patient selection by integrating liquid biopsy, tissue profiling, and nuclear medicine to the already known clinical biomarkers that eventually may lead to a survival improvement. In this paper, the clinical outcomes and inclusion criteria from the most relevant clinical trials and clinical series involving liver transplantation in patients with liver-limited disease colorectal cancer are reviewed as well as the trials currently recruiting.

Identifiants

pubmed: 36879000
doi: 10.1038/s41416-023-02213-1
pii: 10.1038/s41416-023-02213-1
pmc: PMC10147684
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1797-1806

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

BJS Open. 2020 Jun;4(3):467-477
pubmed: 32333527
BJS Open. 2018 Oct 25;3(2):180-185
pubmed: 30957065
JAMA Oncol. 2019 Aug 01;5(8):1124-1131
pubmed: 31070691
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
Transpl Int. 2022 May 30;35:10404
pubmed: 35707633
Ann Surg Oncol. 2015 Aug;22(8):2761-71
pubmed: 25572686
Mol Oncol. 2019 Sep;13(9):1827-1835
pubmed: 31322322
Ann Surg. 2023 Aug 1;278(2):239-245
pubmed: 36082986
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Int J Surg. 2020 Oct;82S:87-92
pubmed: 32305529
Ther Adv Med Oncol. 2021 Feb 22;13:1758835921992974
pubmed: 33747149
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
JAMA Oncol. 2017 Feb 01;3(2):211-219
pubmed: 27787550
Ann N Y Acad Sci. 1994 Sep 15;733:507-14
pubmed: 7978901
Cancer Treat Rev. 2015 Nov;41(9):729-41
pubmed: 26417845
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Transplant Proc. 1991 Feb;23(1 Pt 2):1567-8
pubmed: 1989293
J Natl Cancer Inst. 2011 Jan 5;103(1):21-30
pubmed: 21123833
Ann Oncol. 2017 Aug 01;28(8):1713-1729
pubmed: 28407110
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Nat Rev Clin Oncol. 2020 Jan;17(1):11-32
pubmed: 31289352
Transpl Int. 2021 Nov;34(11):2004-2005
pubmed: 34490945
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Transpl Int. 2021 Nov;34(11):2205-2213
pubmed: 34792825
World J Hepatol. 2015 Oct 8;7(22):2396-403
pubmed: 26464755
Exp Clin Transplant. 2022 Feb;20(2):113-121
pubmed: 35282808
Sci Transl Med. 2016 Jul 6;8(346):346ra92
pubmed: 27384348
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Ann Surg. 2013 May;257(5):800-6
pubmed: 23360920
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Surgery. 2012 Jun;151(6):860-70
pubmed: 22316439
JAMA Oncol. 2019 Dec 1;5(12):1710-1717
pubmed: 31621801
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):218-225
pubmed: 29026950
Ann Surg Oncol. 2014 Apr;21(4):1323-9
pubmed: 24370906
Ann Surg. 2020 May;271(5):e122-e124
pubmed: 32310616
Lancet Gastroenterol Hepatol. 2021 Nov;6(11):933-946
pubmed: 34506756
JAMA Surg. 2022 Jun 1;157(6):524-530
pubmed: 35353121
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
Br J Cancer. 2010 Apr 27;102(9):1313-8
pubmed: 20424612
Clin Nucl Med. 2015 May;40(5):e259-64
pubmed: 25742225
JCO Precis Oncol. 2022 Nov;6:e2200244
pubmed: 36356286
Cancer Commun (Lond). 2020 Sep;40(9):461-464
pubmed: 32762027
Nucl Med Commun. 2020 Sep;41(9):916-923
pubmed: 32796480
Ann Surg. 2019 Aug;270(2):327-332
pubmed: 29916882
Liver Transpl. 2017 Aug;23(8):1073-1076
pubmed: 28544246
J Surg Oncol. 2017 Sep;116(3):288-297
pubmed: 28513862
World J Hepatol. 2016 Jul 28;8(21):874-80
pubmed: 27478537
Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50
pubmed: 15319715
BMC Cancer. 2010 May 11;10:190
pubmed: 20459775
Transpl Int. 2010 Jul;23(7):679-85
pubmed: 20477993
J Natl Cancer Inst. 2014 Jun 12;106(7):
pubmed: 24925349
J Surg Oncol. 2018 Mar;117(4):634-643
pubmed: 29165816
Transplantation. 2017 Apr;101(4S Suppl 2):S1-S56
pubmed: 28328734
Ann Surg. 2006 Aug;244(2):254-9
pubmed: 16858188
Br J Surg. 2018 Feb;105(3):295-301
pubmed: 29168565
Front Surg. 2021 Jul 20;8:693387
pubmed: 34355016
Lancet Oncol. 2022 Oct;23(10):1332-1342
pubmed: 36058227
Ann Oncol. 2017 Aug 01;28(8):1862-1868
pubmed: 28449055
Ann Oncol. 2019 Jul 1;30(7):1173-1177
pubmed: 30977776
Ann Surg. 2020 Feb;271(2):212-218
pubmed: 31188200
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
JAMA Oncol. 2017 Feb 01;3(2):194-201
pubmed: 27722750
Ann Gastroenterol Surg. 2019 Jan 14;3(1):50-56
pubmed: 30697610
Int J Colorectal Dis. 2011 Aug;26(8):967-81
pubmed: 21584664
Transpl Int. 2019 Nov;32(11):1144-1150
pubmed: 31209941
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050

Auteurs

Javier Ros (J)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain. fjros@vhio.net.
Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80131, Naples, Italy. fjros@vhio.net.

Francesc Salva (F)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

Cristina Dopazo (C)

Department of HPB Surgery and Transplants, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autónoma de Barcelona, Barcelona, Spain.

Daniel López (D)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

Nadia Saoudi (N)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

Iosune Baraibar (I)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

Ramon Charco (R)

Department of HPB Surgery and Transplants, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autónoma de Barcelona, Barcelona, Spain.

Josep Tabernero (J)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

Elena Elez (E)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH